

1 **MicroRNA-146a polymorphisms are Associated with Psoriasis Vulgaris**

2 **Running Title:** MicroRNA-146a and Psoriasis

3 **Key words:** Psoriasis Vulgaris; MicroRNA-146a; SNPs; Chinese

4 **Counts:** Manuscript Words count [1680](#); Tables count [3](#); Figures [0](#).

5 **Names of authors:**

6 Kunju Zhu^{1,2#}, Shijie Li², Lifan Liang¹

7 **Names of the institutions:**

8 *1.The Department of Biomedical Informatics;School of medicine; University of Pittsburgh, USA*

9 *2.Department of Dermatology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.*

10 **#Correspondence author:**

11 *Kunju Zhu*

12 **Email:** kunju.pitt@gmail.com

13 **Address:** 5607 Baum Blvd,Pittsburgh, PA 15206-3701

14 **Telephone:** 1-412-403-9009

15 **Any conflict of interest disclosures:**

16 The data is an original data, has not been published before and is not being considered for publication

17 elsewhere. The authors state no conflict of interest.

18 **Abbreviations:**

19 **SNPs:** single nucleotide polymorphisms;

20 **PsV:** psoriasis vulgaris;

21 **PBMCs:** peripheral blood mononuclear cells;

22 **NF- κ B:** nuclear factor-kappaB;

23 **IRAK1:** IL-1 receptor associated kinase 1;

24 **TNF- α :** tumor necrosis factor- α ;

25 **IL:** interleukin;

26 **CI:** confidence interval;

27 **PASI:** Psoriasis Area and Severity Index.

28

29 **Abstract:**

30 MicroRNA-146a acts as a critical physiological brake role to prevent the overactivation
31 of inflammatory response pathways and was a key negative regulator of autoimmunity.
32 Ets-1 could bind to the MicroRNA-146a promoter region as a regulator of
33 MicroRNA-146a expression in vitro. IRAK1 is a prominent target of MicroRNA-146a
34 that help it to negatively regulate the release of IL8. This study aimed to investigate the
35 association of MicroRNA-146a, Ets-1(negative regulator) and IRAK1(target)
36 polymorphisms with Psoriasis Vulgaris(*PsV*), the most prevalent chronic inflammatory
37 skin disease in adults, in a Southern Chinese cohort. Seven SNPs in microRNA-146a
38 (rs2431697; rs2910164; rs57095329), Ets-1(rs10893872; rs1128334) and
39 IRAK1(rs1059703; rs3027898) genes were genotyped in 673 subjects (360 PsV cases
40 and 313 controls) by SNaPshot Multiplex Kit (Applied Biosystems Co., USA). We found
41 significant difference in the genotype and allele frequencies of rs2431697 and rs2910164
42 in MicroRNA-146a gene between the PsV cases and the controls. The dominant model
43 genotype (CC+CT) ($p=0.019$; OR=1.463) and allele (C) ($p=0.027$; OR=1.496) of
44 rs2431697 and the GG genotype ($p= 0.027$; OR=1.582) and allele (G) of rs2910164 were
45 associated with an increased risk of PsV. There was no association of the SNPs with the
46 clinical traits of PsV. Our data provide preliminary evidence that the rs2431697 and
47 rs2910164 polymorphism in the microRNA-146a gene may be involved in the genetic
48 susceptibility to PsV in Southern Chinese. Although further function studies will be
49 required to identify the details of the process, the findings could make a significant step
50 forward in our understanding of the genetic contribution to psoriasis.

51

52

53 What's already known about this topic?

- 54 ● MicroRNA-146a is one of the most highly associated MicroRNA to psoriasis.
55 ● MicroRNA-146a acts as a critical physiological brake role to prevent the overactivation
56 of inflammatory response pathways and was a key negative regulator of autoimmunity.

57

58

59 **What does this study add?**

- 60 ● Our data provide preliminary evidence that the rs2431697 and rs2910164 polymorphism
61 in the microRNA-146a gene are involved in the genetic susceptibility to PsV in
62 Southern Chinese.

63

64 **Introduction:**

65 Psoriasis is one of the most common skin disorders resulting from a complex interplay
66 among the susceptibility genes and autoimmune system¹. Psoriasis vulgaris (PsV), the most
67 common subtype of psoriasis, is characterized by the emergence of hyperkeratosis,
68 parakeratosis and orthokeratosis². However, the molecules pathogenesis of psoriasis is still
69 not completely elucidated.

70 The microRNAs represent a class of is short and regulatory RNAs that regulate RNA
71 silencing and post-transcriptional process. Recently studies have also shown that the
72 noncoding RNAs (including microRNAs) may be a crucial regulator in human life and so
73 many human diseases³. Furthermore, the majority of protein-coding genes may be regulated
74 by microRNAs. Accordingly, microRNAs have been implicated in almost all biological
75 processes, in particular cell differentiation, development and the signaling pathways³. In
76 recent years, evidence is accumulating for the role of microRNAs in the pathogenesis of
77 psoriasis rapidly⁴. Specifically, many studies have confirmed that single nucleotide
78 polymorphisms (SNPs) located in microRNAs genes associated with the susceptibility to
79 psoriasis^{4,5}.

80 Of the susceptibility microRNAs to psoriasis, MicroRNA-146a is one of the most highly
81 associated MicroRNA to psoriasis⁶⁻⁸. Several studies have found that MicroRNA-146a
82 Increased both in the epidermal and dermal compartments of psoriatic skin^{7,9}.
83 Chatzikiyriakidou *et al*¹⁰ have shown the association between psoriatic arthritis risk in a
84 cohort of patients with psoriasis from Greece and specific polymorphisms found in
85 MicroRNA-146a (rs2910164) and one of its targets IRAK1 (rs3027898, rs1059703). In his
86 study, a very strong association with the rs3027898 IRAK1 variant was also observed¹⁰.
87 Specifically, the rs2910164G allele resulted in reduced levels of MicroRNA-146a and
88 impairment of its ability to regulate endothelial growth factor receptor, an important
89 proliferative signal in keratinocytes and psoriasis skin¹¹.

90 On the other hand, previously study have identified that ETS proto-oncogene 1,

91 transcription factor (ETS1) could affects MicroRNA-146a promoter activity markedly in
92 vitro, by binding the MicroRNA-146a promoter region¹². Furthermore, knockdown of ETS1
93 impaired the induction of miR-146a, whereas overexpression of ETS1 enhanced the
94 induction of MicroRNA-146a in vivo experiments. Actually, ETS1 is involved in various
95 immune responses. ETS1 plays a role in immunity, angiogenesis, and cancer progression,
96 and is expressed in B cells, T cells, natural killer cells, endothelial cells, and cancer cells¹³⁻¹⁵.
97 In T cells, reduction of T helper (Th) 1 cytokine, interferon γ , and decrease in regulatory T
98 cells (Tregs) were observed in Ets1-deficient mice. On the other hand, Th17 differentiation
99 was enhanced by Ets1 deficiency¹³⁻¹⁵. It has also been shown that SNP rs1128334 and
100 rs10893872 located in the 3'-untranslated region (3'-UTR) of Ets-1 are on putative miRNA
101 binding sites and are both associated with SLE in Asian populations¹². All these results may
102 suggest that Ets-1 influences the activity of MicroRNA-146a and it may take some role in the
103 immunity pathogenesis of psoriasis.

104 In this study, we aimed to examined the association of MicroRNA-146a, Ets-1(its
105 negative regulator) and IRAK1(its target) gene polymorphisms with PsV in a Southern Han
106 Chinese cohort.

107

108

109 **Materials and methods**

110 **Clinical evaluation and Anthropometric measurements of patients and controls**

111 The detailed method of clinical characteristics evaluation and anthropometric measurements
112 had been described previously¹⁶. In shortly, General information of all subjects include age,
113 gender, family history, Psoriasis Area and Severity Index (PASI)^{17,18} were recorded. The
114 positive family history was considered if at least one of the first- and second-degree relatives
115 was suffered from psoriasis. PASI score below 6 was defined as mild, and above 6 as severe
116 disease based on median distribution. A total of 360 cases and 313 controls at age of 15 years
117 or more were recruited from 2009 to 2016 in Southern China. The study protocol was
118 approved by the ethical committee of Affiliated Hospital of Guangdong Medical University
119 in compliance with the Helsinki Declaration, and written informed consents were obtained
120 from all participants.

121 **DNA isolation and genotyping**

122 Genomic DNAs were extracted in accordance with standard protocols from peripheral blood
123 cells by established method¹⁹. Genotyping of 7 SNPs in microRNA-146a (rs2431697;
124 rs2910164; rs57095329), IRAK1 (rs1059703; rs3027898), Ets-1(rs10893872; rs1128334)
125 genes were determined using SNaPshot Multiplex Kit (Applied Biosystems Co., USA).

126 **Statistical analyses**

127 $P < 0.05$ was the criterion of statistical significance, and all statistical tests were two-sided.
128 Characteristics differences between cases and controls were assessed with the *t* test, the
129 Pearson's Chi-square test by the SPSS 13.0. The SNP was analyzed for an association with
130 the disease by means of comparison frequency of the minor allele and genotypes, and
131 Hardy–Weinberg equilibrium among controls was confirmed with Chi-squared test for all
132 SNPs. We also performed case-only subtype analyses to examine associations between two
133 significant SNPs genotypes with the clinical traits of PsV.

134

135

136 **Results**

137 **Subjects characteristics**

138 A total of 360 cases (275 men: 185 women; 37.63 ± 15.33 years) and 313 controls (185 men:
139 128 women; 35.77 ± 14.87 years) were investigated and matched on age and sex ($p > 0.05$). For
140 patients, PASI (8.83 ± 7.57), age of onset (30.44 ± 16.06 and 258 Early-onset (≤ 40 years): 102
141 Later-onset (> 40 years)) and family history (ratio of familial: sporadic cases=75:285) was
142 recorded (**Table 1**).

143

144 **Association between seven polymorphisms and the risk of PsV**

145 The genotype frequency distributions for 7 SNPs investigated were consistent with
146 Hardy-Weinberg equilibrium in the control group ($p > 0.05$). The comparison of allele
147 distributions revealed that two SNPs (rs2431697, rs2910164) of them were significant
148 associated with the risk of PsV ($p < 0.05$). For rs2431697, the minor allele C was present in
149 15.56% of patients and 11.18% of controls; and significant differences was also observed in
150 dominance model ($p < 0.01$), but the recessive model is not. Then for rs2910164, the minor
151 allele G was present in 43.75% of patients and 36.90% of controls; and significant
152 differences was also observed in recessive model ($p < 0.01$), but the dominance model is not
153 (**Table 2**).

154

155 **Association between two risk SNPs (rs2431697, rs2910164) associated with the clinical**

156 We further performed a stratified analysis according to the age of onset, family history and
157 PASI subphenotypes to detect the distribution of the rs2431697 and rs2910164 genotypes in
158 clinical phenotype of PsV. However, there were no significant differences found in
159 subphenotypes of family history or PASI between patients positive and those negative for a
160 particular phenotype (**Table 3**).

161

162

163 **Discussion:**

164 We conducted the study to evaluate the association between 7 SNPs of MicroRNA-146a
165 gene, Ets-1(its negative regulator) and IRAK1(its target) polymorphisms and risk factors on
166 PsV.

167 As we know, MicroRNAs are an abundant class of small noncoding RNA molecules, and
168 have been recently recognized as an important regulator in immune homeostasis ³. As
169 MicroRNA-146a is a crucial negative regulator of the immune response by negatively
170 regulating *NF-κB* dependent inflammatory signals via direct targeting of IL-1
171 receptoreassociated kinase 1 (IRAK1) ^{20,21}. *NF-κB* is a protein transcription factor and a key
172 regulatory element in a variety of immune and inflammatory pathways, in cellular
173 proliferation and differentiation. Furthermore, *NF-κB* has been hypothesized to connect the
174 altered keratinocyte and immune cell behavior that characterizes the psoriatic milieu ^{21,22}.

175 Moreover, recent studies have demonstrated that SNPs located either in the pre-miRNAs
176 or within miRNA binding sites may contribute to the susceptibility to diseases. Within
177 MicroRNA-146a , several SNPs (rs2910164 and rs2431697) which could lead to the
178 alteration of microRNA function or expression have been noted^{23,24}. Specifically, rs2910164
179 in the pre-miRNA sequence is thought to result in reduced levels of both the pre and mature
180 miRNA. And previously studied found the association between psoriatic arthritis risk in a
181 cohort of patients with psoriasis from Greece and specific polymorphisms found in
182 microRNA-146a (rs2910164) and one of its known targets, IRAK1 (rs3027898, rs1059703)
183 ¹⁰. In contrast, a separate study showed that the rs2910164 microRNA-146a allele was
184 associated with increased psoriasis susceptibility in Han Chinese patients¹¹. The rs2910164
185 variant C-allele also play a role in the progression of PsA in the South African Indian
186 population²⁵. Specifically, the rs2910164G allele resulted in reduced levels of
187 microRNA-146a and impairment of its ability to regulate endothelial growth factor receptor,
188 an important proliferative signal in keratinocytes and psoriasis skin ¹¹. Srivastava *et al* report
189 protective association of a functional polymorphism in the MicroRNA-146a precursor
190 (rs2910164). Genetic deficiency in MicroRNA-146a leads to earlier onset and exacerbated
191 pathology of skin inflammation, with increased expression of IL-17–induced

192 keratinocyte-derived inflammatory mediators, epidermal hyperproliferation, and increased
193 neutrophil infiltration. Moreover, they also shown that MicroRNA-146a –deficient mice do
194 not resolve inflammation after discontinuation of imiquimod challenge. The overexpression
195 of MicroRNA-146a suppressed, whereas its inhibition enhanced, IL-17–driven inflammation
196 in keratinocytes. Functionally, MicroRNA-146a impairs the neutrophil chemoattractant
197 capacity of keratinocytes. Finally, delivery of MicroRNA-146a mimics into the skin leads to
198 amelioration of psoriasiform skin inflammation, decreased epidermal proliferation, and
199 neutrophil infiltration. Their results define a crucial role for MicroRNA-146a in modulating
200 IL-17–driven inflammation in the skin²³.

201 In addition, strong evidence indicates that rs2910164 leads to increased or decreased
202 microRNA-146a expression in a cell type-dependent manner. For instance, Jazdzewski et al.
203 reported that rs2910164 C allele displayed a 1.8-fold lower level of mature MicroRNA-146a
204 compared to those harboring the G allele²⁶. Likewise, Xu et al. found that the G-allelic
205 MicroRNA-146a precursor yielded more mature MicroRNA-146a compared to the C
206 allelic precursor in the 293T cell line²⁷. On the other hand, Shen et al. found that
207 MicroRNA-146a expression was 60% higher in the C allele than the G allele in the MCF-7
208 cell, a model system for breast cancer²⁸. The disparate effects of the rs2910164 C allele on
209 the expression level of MicroRNA-146a may explain the equally disparate effects the SNP
210 has on autoimmune diseases that are localized to different tissues or affect different cell
211 types such as psoriasis and ankylosing spondylitis²⁴.

212 In our study, we found the allele and genotypes of rs2910164 and rs2431697 of
213 MicroRNA-146a associated with the risk of PsV. The associations of the other SNPs within
214 the susceptibility loci remain unclear and further studies are necessary to achieve better
215 understanding the genetic components of PsV. Despite the fact that the function experiments
216 were not carrying out to further illustrate this phenomenon from the level of genetic
217 epidemiology. The findings could make a significant step forward in our understanding of
218 the genetic contribution to psoriasis.

219

220 **Acknowledgment:**

221 We are most grateful to the members of all the patients, the controls and their families who
222 have so willingly participated in this study. This work was supported by grants from the
223 China Natural Science Foundation (**No. 81301351**). The funders had no role in study
224 design, data collection and analysis, decision to publish, or preparation of the manuscript.

225

226

227

228

229 **References:**

- 230 1 Schon MP, Boehncke WH. Psoriasis. *N Engl J Med* 2005; **352**: 1899-912.
- 231 2 Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. *J Invest Dermatol* 1994; **102**:
232 14S-8S.
- 233 3 Esteller M. Non-coding RNAs in human disease. *Nature reviews. Genetics* 2011; **12**: 861-74.
- 234 4 Hawkes JE, Nguyen GH, Fujita M *et al.* microRNAs in Psoriasis. *J Invest Dermatol* 2016; **136**:
235 365-71.
- 236 5 Sonkoly E, Stahle M, Pivarsci A. MicroRNAs: novel regulators in skin inflammation. *Clin Exp*
237 *Dermatol* 2008; **33**: 312-5.
- 238 6 Sonkoly E, Wei T, Janson PC *et al.* MicroRNAs: novel regulators involved in the pathogenesis of
239 psoriasis? *PLoS One* 2007; **2**: e610.
- 240 7 Xia J, Joyce CE, Bowcock AM *et al.* Noncanonical microRNAs and endogenous siRNAs in normal
241 and psoriatic human skin. *Hum Mol Genet* 2013; **22**: 737-48.
- 242 8 Zibert JR, Lovendorf MB, Litman T *et al.* MicroRNAs and potential target interactions in psoriasis. *J*
243 *Dermatol Sci* 2010; **58**: 177-85.
- 244 9 Lovendorf MB, Mitsui H, Zibert JR *et al.* Laser capture microdissection followed by next-generation
245 sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA
246 changes in psoriasis. *Exp Dermatol* 2015; **24**: 187-93.
- 247 10 Chatzikiyriakidou A, Voulgari PV, Georgiou I *et al.* The role of microRNA-146a (miR-146a) and its
248 target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. *Scandinavian journal of*
249 *immunology* 2010; **71**: 382-5.
- 250 11 Zhang W, Yi X, Guo S *et al.* A single-nucleotide polymorphism of miR-146a and psoriasis: an
251 association and functional study. *J Cell Mol Med* 2014; **18**: 2225-34.
- 252 12 Luo X, Yang W, Ye DQ *et al.* A functional variant in microRNA-146a promoter modulates its
253 expression and confers disease risk for systemic lupus erythematosus. *PLoS Genet* 2011; **7**: e1002128.
- 254 13 Garrett-Sinha LA. Review of Ets1 structure, function, and roles in immunity. *Cell Mol Life Sci* 2013;
255 **70**: 3375-90.
- 256 14 Kawasaki A, Yamashita K, Hirano F *et al.* Association of ETS1 polymorphism with granulomatosis
257 with polyangiitis and proteinase 3-anti-neutrophil cytoplasmic antibody positive vasculitis in a
258 Japanese population. *J Hum Genet* 2018; **63**: 55-62.
- 259 15 Russell L, Garrett-Sinha LA. Transcription factor Ets-1 in cytokine and chemokine gene regulation.
260 *Cytokine* 2010; **51**: 217-26.
- 261 16 Zhu K-J, Liu Z, Liu H *et al.* An association study on the CHRNA5/A3/B4 gene cluster, smoking and
262 psoriasis vulgaris. *Archives of dermatological research* 2014; **306**: 939-44.
- 263 17 Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica* 1978;
264 **157**: 238-44.
- 265 18 Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global
266 Assessment, and Lattice System Physician's Global Assessment. *J Am Acad Dermatol* 2004; **51**:
267 563-9.
- 268 19 Grimberg J, Nawoschik S, Belluscio L *et al.* A simple and efficient non-organic procedure for the
269 isolation of genomic DNA from blood. *Nucleic Acids Res* 1989; **17**: 8390.
- 270 20 Meisgen F, Xu Landen N, Wang A *et al.* MiR-146a negatively regulates TLR2-induced inflammatory
271 responses in keratinocytes. *J Invest Dermatol* 2014; **134**: 1931-40.
- 272 21 O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. *Annu Rev*

273 *Immunol* 2012; **30**: 295-312.

274 22 Taganov KD, Boldin MP, Chang KJ *et al.* NF-kappaB-dependent induction of microRNA miR-146, an
275 inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci U S A* 2006;
276 **103**: 12481-6.

277 23 Srivastava A, Nikamo P, Lohcharoenkal W *et al.* MicroRNA-146a suppresses IL-17-mediated skin
278 inflammation and is genetically associated with psoriasis. *J Allergy Clin Immunol* 2017; **139**: 550-61.

279 24 Park R, Lee WJ, Ji JD. Association between the three functional miR-146a single-nucleotide
280 polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A
281 meta-analysis. *Autoimmunity* 2016; **49**: 451-8.

282 25 Maharaj AB, Naidoo P, Ghazi T *et al.* MiR-146a G/C rs2910164 variation in South African Indian and
283 Caucasian patients with psoriatic arthritis. *BMC medical genetics* 2018; **19**: 48.

284 26 Jazdzewski K, Murray EL, Franssila K *et al.* Common SNP in pre-miR-146a decreases mature miR
285 expression and predisposes to papillary thyroid carcinoma. *Proc Natl Acad Sci U S A* 2008; **105**:
286 7269-74.

287 27 Xu T, Zhu Y, Wei QK *et al.* A functional polymorphism in the miR-146a gene is associated with the
288 risk for hepatocellular carcinoma. *Carcinogenesis* 2008; **29**: 2126-31.

289 28 Shen J, Ambrosone CB, DiCioccio RA *et al.* A functional polymorphism in the miR-146a gene and
290 age of familial breast/ovarian cancer diagnosis. *Carcinogenesis* 2008; **29**: 1963-6.

291

292

293 **TABLES LEGENDS**

294 **Table 1.** The characteristics of PsV cases and controls

295 **Table 2.** OR estimates of effects on the risk of PsV

296 **Table 3.** OR estimates of risk SNPs genotypes on the clinical traits of PsV.

297

298

Table 1. The characteristics of PsV cases and controls

Variables	Cases (n = 360)	Controls (n = 313)	p-Value
Age(mean±sd, years)	37.63±15.33	35.77±14.87	0.54
Females, n	185	128	0.85
Males, n	275	185	
PASI score (mean±sd)	8.63±7.57	-	-
Mean age of onset (mean±sd, years)	30.44±16.06	-	-
Early-onset (≤ 40 years) , n	256	-	-
Later-onset (> 40 years), n	99	-	-
Familial cases, n	74	-	-
Sporadic cases, n	281	-	-

PASI ;Psoriasis Area and Severity Index

χ² -test for categorical variables.

t-test for quantitative variables;

299

300

Table 2. OR estimates of effects on the risk of PsV

Gene	SNPs	Comparisons	Minor allele and Genotype				OR(95% CI)	p-Value
			Frequency					
			Cases(n=360)	Controls(n=313)				
MicroRNA-146a	rs2431697	C(vs.T)	112	15.56%	70	11.18%	1.463(1.062-2.015)	0.019*
		CC(vs.CT+TT)	12	3.33%	6	1.92%	1.764(0.654-4.757)	0.256
		CC+CT(vs.TT)	100	27.78%	64	20.45%	1.496(1.045-2.142)	0.027*
MicroRNA-146a	rs2910164	G(vs.C)	315	43.75%	231	36.90%	1.330(1.068-1.656)	0.011*
		GG(vs.GC+CC)	74	20.56%	44	14.06%	1.582(1.051-2.380)	0.027*
		GG+GC(vs.CC)	241	66.94%	187	59.74%	1.365(0.996-1.870)	0.053
MicroRNA-146a	rs57095329	G(vs.A)	139	19.31%	139	22.20%	0.838(0.644-1.092)	0.190
		GG(vs.GA+AA)	12	3.33%	17	5.43%	0.600(0.282-1.277)	0.181
		GG+GA(vs.AA)	127	35.28%	122	38.98%	0.853(0.624-1.168)	0.321
IRAK1	rs1059703	A(vs.G)	149	20.69%	146	23.32%	0.858(0.662-1.111)	0.245
		AA(vs.AG+GG)	51	14.17%	52	16.61%	0.828(0.544-1.261)	0.379
		AA+AG(vs.GG)	98	27.22%	94	30.03%	0.871(0.623-1.218)	0.421
IRAK1	rs3027898	A(vs.C)	145	20.14%	140	22.36%	0.875(0.674-1.137)	0.319
		AA(vs.AC+CC)	51	14.17%	50	15.97%	0.868(0.569-1.326)	0.512
		AA+AC(vs.CC)	94	26.11%	90	28.75%	0.876(0.624-1.229)	0.443
ETS-1	rs10893872	C(vs.T)	292	40.56%	272	43.45%	0.888(0.715-1.103)	0.283
		CC(vs.CT+TT)	58	16.11%	61	19.49%	0.793(0.534-1.179)	0.252
		CC+CT(vs.TT)	234	65.00%	211	67.41%	0.898(0.652-1.237)	0.510
ETS-1	rs1128334	T(vs.C)	252	35.00%	239	38.18%	0.872(0.698-1.089)	0.227
		TT(vs.TC+CC)	49	13.61%	50	15.97%	0.829(0.541-1.270)	0.388
		TT+TC(vs.CC)	203	56.39%	189	60.38%	0.848(0.624-1.154)	0.295

301

302 **Table 3: OR estimates of risk SNPs genotypes on the clinical traits of PsV**
 303

SNPs	Genotypes Frequency of Cases	Early-onset (≤ 40 years) VS. Later-onset (> 40 years)		Familial cases VS. Sporadic cases		Mild (PASI ≤ 6) VS. Severe(PASI > 6)	
		<i>p</i> value	OR(95% CI)	<i>p</i> value	OR(95% CI)	<i>p</i> value	OR(95% CI)
		rs2431697					
CC	12(3.33%)		1 (referent)		1 (referent)		1 (referent)
CT	88(24.44%)	0.261	0.495(0.143-1.716)	0.251	2.25(0.603-8.396)	0.693	1.278(0.377-4.336)
TT	260(72.22%)	0.325	0.557(0.171-1.811)	0.298	1.864(0.541-6.418)	0.520	1.466(0.454-4.739)
rs2910164							
GG	74(20.56%)		1 (referent)		1 (referent)		1 (referent)
CG	167(46.39%)	0.056	1.880(0.978-3.611)	0.338	0.704(0.343-1.447)	0.562	0.850(0.492-1.471)
CC	119(33.06%)	0.244	1.509(0.754-3.023)	0.276	0.659(0.311-1.400)	0.830	1.066(0.596-1.905)

304
 305
 306
 307
 308
 309
 310
 311
 312

OR: odds ratio;
 CI: confidence interval;
 PASI: Psoriasis Area and Severity Index.
 Based on median distribution, PASI < 6.0 was defined as mild psoriasis and 6.0 as severe psoriasis.